Document/ExhibitDescriptionPagesSize
1: 8-K Current Report HTML 29K
2: EX-99.1 Press Release HTML 73K
3: EX-99.2 Presentation HTML 17K
10: R1 Document and Entity Information HTML 48K
12: XML IDEA XML File -- Filing Summary XML 12K
9: XML XBRL Instance -- cdxc-20601231_htm XML 16K
11: EXCEL IDEA Workbook of Financial Reports XLSX 6K
5: EX-101.CAL XBRL Calculations -- cdxc-20601231_cal XML 8K
6: EX-101.DEF XBRL Definitions -- cdxc-20601231_def XML 10K
7: EX-101.LAB XBRL Labels -- cdxc-20601231_lab XML 48K
8: EX-101.PRE XBRL Presentations -- cdxc-20601231_pre XML 34K
4: EX-101.SCH XBRL Schema -- cdxc-20601231 XSD 13K
13: JSON XBRL Instance as JSON Data -- MetaLinks 12± 19K
14: ZIP XBRL Zipped Folder -- 0001654954-21-005215-xbrl Zip 21K
ChromaDex Corporation Reports First Quarter 2021 Financial
Results
Tru Niagen® Revenue for the Three-Month Period Ended March 31,2021 Totals $12.4 Million, up 12% Year-over-Year, with Total
Company Revenue of $14.7 Million and Gross Margin of
62.9%.
LOS ANGELES, May 6, 2021 (GLOBE NEWSWIRE) - ChromaDex Corp. (NASDAQ:CDXC)
today
reported first quarter 2021 financial results.
First Quarter 2021 and Recent Highlights
●
Total net sales of $14.7 million, up 2% from $14.3 million in the
year ago quarter.
●
Tru Niagen® net sales of $12.4 million, a 12% increase from
the year ago quarter.
●
Gross margin of 62.9%, a 500 basis point increase from the year ago
quarter.
●
Net loss was ($7.4) million or ($0.12) per share, down $0.02 per
share year-over-year.
●
Adjusted EBITDA
excluding total legal expense, a non-GAAP measure, was a loss of
($0.7) million, a $0.4 million decline year-over-year.
●
Announced retail
distribution of Tru Niagen® in Walmart™ stores across
the United States beginning in June 2021.
●
Announced strategic
supply agreement with Health & Happiness Group (H&H), a
global leader in premium health, human and pet nutrition and
personal care brands to sell Niagen® in its exclusively
formulated Swisse™ products.
●
Announced strategic
supply agreement with Ro, a healthcare technology company, to sell
Niagen® in specially-formulated Roman products.
●
Appointed former
Nestlé
executive, Fadi Karam as Chief Marketing
Officer.
●
Appointed Dr. David
L. Katz, a globally recognized authority on lifestyle medicine, to
the ChromaDex Scientific Advisory Board.
“This
has been an incredible year for ChromaDex strategically,”
said ChromaDex CEO, Rob Fried. “We signed three
important deals with Walmart, H&H, and Ro. We also
strengthened our balance sheet with a $25 million capital raise and
announced the results of exciting scientific research on
Niagen®. We had some short-term supply chain disruptions
that impacted first quarter sales, but the long-term prospects look
stronger than ever.”
Results of operations for the three months ended March 31,2021
For the
three months ended March 31, 2021 (“Q1 2021”),
ChromaDex reported net sales of $14.7 million, up 2% compared to
$14.3 million in the first quarter of 2020 ("Q1 2020"). The
increase in Q1 2021 revenues was driven by growth in sales of Tru
Niagen®, largely offset by lower
Niagen® and other ingredient sales.
Gross
margin percentage improved by 500 basis points to 62.9% in Q1 2021
compared to 57.9% in Q1 2020. The improvement in gross margin
percentage was driven by the positive impact of increased Tru
Niagen® consumer
product sales and product cost savings initiatives.
Operating
expenses increased by $2.4 million to $16.6 million in Q1 2021,
compared to $14.2 million in Q1 2020. The increase in operating
expenses was driven by $1.8 million of higher selling and marketing
expenses, and an increase of $0.7 million in general and
administrative expense, partially offset by $0.1 million of lower
research and development expense. The increase in general and
administrative expense was driven by $2.6 million of higher legal
expense, partially offset by $1.0 million of lower severance and
restructuring expenses and $0.8 million of lower shares-based
compensation expense.
The net
loss for Q1 2021 was ($7.4) million or ($0.12) per share as
reported compared to a net loss of ($5.9) million or ($0.10) per
share for Q1 2020 as reported. Adjusted EBITDA excluding total
legal expense, a non-GAAP measure, was a loss of ($0.7) million for
Q1 2021, compared to a loss of ($0.3) million for Q1 2020, a $0.4
million decline.
ChromaDex
defines Adjusted EBITDA excluding total legal expense as net income
or (loss) which is adjusted for interest, income tax, depreciation,
amortization, non-cash stock compensation costs, severance and
restructuring expense, bad debt expense related to Elysium Health
and total legal expense.
For Q1
2021, the net cash flow from operating activities was ($5.4)
million, versus ($5.2) million in Q1 2020.
2021
Outlook
Looking
forward, for the full year, the Company expects continued, steady
revenue growth driven by its global ecommerce business, as well as
growth with existing and new strategic partners, and that the
growth rate will accelerate beginning in the second quarter.
The Company expects continued gross margin improvement to slightly
better than 60%, roughly flat R&D expense and slightly higher
selling and marketing expense as a percentage of net sales
year-over-year. The Company expects slightly higher general and
administrative expense, excluding severance, restructuring and
legal expense. The Company plans to increase investments and
resources to drive brand awareness and accelerate its R&D
pipeline to capitalize on growth in the NAD+ market
globally.
Investor Conference Call
ChromaDex management will host an investor conference call to
discuss the first quarter results and provide a general business
update on Thurs., May 6, at 4:30 p.m. ET.
Participants should call in at least 10 minutes prior to the call.
The dial-in information is as follows:
Webcast link: ChromaDex First
Quarter 2021 Earnings Conference Call
The conference call will be broadcast live and available for
replay here and
via the investor relations section of the Company’s website
at www.chromadex.com.
A replay of the conference call will be available after 7:30
p.m. ET.
Adjusted
EBITDA excluding total legal expense excludes interest, income tax,
depreciation, amortization, non-cash share-based compensation
costs, severance and restructuring expense and total legal expense.
ChromaDex uses these non-GAAP measures when evaluating its
financial results as well as for internal resource management,
planning and forecasting purposes. ChromaDex believes the
presentation of its non-GAAP financial measures enhances the
overall understanding of the company’s historical financial
performance. These non-GAAP measures should not be viewed in
isolation from or as a substitute for ChromaDex’s financial
results in accordance with GAAP. Reconciliation of GAAP to non-GAAP
measures are attached to this press release.
About ChromaDex:
ChromaDex
Corp. is a global bioscience company dedicated to healthy aging.
The ChromaDex team, which includes world-renowned scientists, is
pioneering research on nicotinamide adenine dinucleotide (NAD+),
levels of which decline with age. ChromaDex is the innovator behind
NAD+ precursor nicotinamide riboside (NR), which is protected by
ChromaDex’s patent portfolio along with other NAD+
precursors. ChromaDex maintains a website at www.chromadex.com to
which ChromaDex regularly posts copies of its press releases as
well as additional and financial information about the
Company.
Important Note on Forward Looking Statements:
This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities and Exchange Act of 1934, as amended. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Such statements include the
quotation from ChromaDex’s Chief Executive Officer, and
statements related to the company’s 2021 financial outlook.
Other risks that contribute to the uncertain nature of the
forward-looking statements are reported in our most recent
Quarterly Report on Form 10-Q and Annual Report on Form 10-K as
filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof, and actual results may differ materially from
those suggested by these forward-looking statements. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ChromaDex undertakes no obligation to
revise or update this release to reflect events or circumstances
after the date hereof.
ChromaDex Investor Relations Contact:
Brianna
Gerber, Vice President of Finance and Investor
Relations
Basic
and diluted weighted average common shares outstanding
64,164
59,782
See
Notes to Consolidated Financial Statements in Part I Item 1 of
ChromaDex's Quarterly Report on Form 10-Q to be filed with
Securities and Exchange Commission on May 6, 2021.
Cash,
including restricted cash of $0.2 million and $0.2 million,
respectively
$44,691
$16,697
Trade receivables, net of allowances of $0.2 million and $0.2
million, respectively;
Receivables
from Related Party: $1.3 million and $0.9 million,
respectively
4,647
2,694
Inventories
12,762
11,683
Prepaid
expenses and other assets
1,119
1,145
Total current assets
63,219
32,219
Leasehold
Improvements and Equipment, net
3,058
3,206
Intangible
Assets, net
1,022
1,082
Right
of Use Assets
1,100
1,226
Other
Long-term Assets
594
625
Total assets
$68,993
$38,358
Liabilities and Stockholders' Equity
Current
Liabilities
Accounts
payable
$11,693
$9,445
Accrued
expenses
7,328
6,133
Current
maturities of operating lease obligations
485
589
Current
maturities of finance lease obligations
19
31
Customer
deposits
231
278
Total current liabilities
19,756
16,476
Deferred
Revenue
4,441
4,441
Operating
Lease Obligations, Less Current Maturities
947
997
Finance
Lease Obligations, Less Current Maturities
17
20
Total liabilities
25,161
21,934
Commitments
and Contingencies
Stockholders'
Equity
Common
stock, $.001 par value; authorized 150,000 shares;
issued
and outstanding March 31, 2021 67,702 shares and
December
31, 2020 61,881 shares
68
62
Additional
paid-in capital
192,972
158,190
Accumulated
deficit
(149,206)
(141,825)
Cumulative
translation adjustments
(2)
(3)
Total stockholders' equity
43,832
16,424
Total liabilities and stockholders' equity
$68,993
$38,358
See
Notes to Consolidated Financial Statements in Part I Item 1 of
ChromaDex's Quarterly Report on Form 10-Q to be filed with
Securities and Exchange Commission on May 6, 2021.